Synergistic Anticancer Effects of the PLK1 Inhibitor BI-2536 and β-Glucan in Colon and Gastric Cancer Cells
Rabia Gökçe Takci1, Bülent Saraç1, Levent Hacisüleyman2
1Faculty of Medicine, Sivas Cumhuriyet University, Sivas, Türkiye.
Background/Aim:
Colon and gastric cancers are among the most prevalent gastrointestinal malignancies, often exhibiting poor prognosis due to resistance and recurrence. Polo-like kinase 1 (PLK1), a key regulator of mitosis, is frequently overexpressed in these cancers. BI-2536, a selective PLK1 inhibitor, has shown promising anticancer activity. β-Glucan, a natural immunomodulator, has also demonstrated anticancer potential. This study aimed to evaluate the antiproliferative, apoptotic, and cell cycle effects of BI-2536 alone and in combination with β-glucan on HT-29 colon and AGS gastric cancer cell lines.
Materials And Methods:
Cell viability was assessed using the XTT assay. Apoptosis and cell cycle profiles were evaluated using flow cytometry. The combination index (CI) was calculated using the Chou-Talalay method via CompuSyn software.
Results:
BI-2536 significantly inhibited proliferation and induced G2/M arrest and apoptosis in both cell lines. β-Glucan showed moderate cytotoxicity and enhanced BI-2536's effects. Synergistic antiproliferative activity was observed at lower drug concentrations, such as 2-16 nM BI-2536 combined with 31.25-250 μg/ml β-glucan (CI<1). The combination induced greater apoptosis and more pronounced G2/M arrest compared with either agent alone, demonstrating a clear synergistic effect.
Conclusion:
BI-2536 in combination with β-glucan exhibits synergistic anticancer effects in vitro, suggesting a promising strategy for treating colon and gastric cancers.
Insights
The combination of BI-2536, a PLK1 inhibitor, and β-glucan shows synergistic anticancer effects against colon and gastric cancer cells. This combination therapy effectively reduces proliferation and induces apoptosis, offering a promising new treatment strategy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Colon and gastric cancers are leading gastrointestinal malignancies with poor prognoses due to treatment resistance and recurrence.
- Polo-like kinase 1 (PLK1), a critical regulator of mitosis, is overexpressed in these cancers.
- BI-2536 (PLK1 inhibitor) and β-glucan (immunomodulator) have demonstrated individual anticancer potential.
Purpose of the Study:
- To evaluate the antiproliferative and apoptotic effects of BI-2536 and β-glucan.
- To assess the impact on cell cycle progression in colon (HT-29) and gastric (AGS) cancer cell lines.
- To determine the synergistic potential of combining BI-2536 with β-glucan.
Main Methods:
- Cell viability assessed via XTT assay.
- Apoptosis and cell cycle analysis conducted using flow cytometry.
- Combination Index (CI) calculated using Chou-Talalay method with CompuSyn software.
Main Results:
- BI-2536 significantly inhibited proliferation and induced G2/M arrest and apoptosis in both cell lines.
- β-Glucan demonstrated moderate cytotoxicity and enhanced BI-2536's effects.
- The combination therapy exhibited synergistic antiproliferative activity (CI<1) at specific concentrations, inducing greater apoptosis and G2/M arrest than individual agents.
Conclusions:
- BI-2536 combined with β-glucan demonstrates synergistic anticancer effects *in vitro*.
- This combination represents a promising therapeutic strategy for colon and gastric cancer treatment.
More Related Videos
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:15Drugs that Stabilize Microtubules